Biogen shrugs off $1B-plus gene therapy pact after PhI/II implosion — AGTC shares crater
More than 3 years after Biogen $BIIB fronted their $1 billion-plus pact with Florida-based biotech AGTC with $124 million in cash to build their new …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
